• Search
      • Search Interactions Search Categories
    • Browse
      • Browse Categories Browse Sources
    • Information
      • About Publications Interaction Types & Directionalities Interaction Score & Query Score API Documentation FAQ Known Data Clients News Contact
    • Downloads
      • Data Source Code

ETHOSUXIMIDE Drug Record

  • Summary
  • Interactions
  • Claims
  • ETHOSUXIMIDE chembl:CHEMBL696 Approved

    Alternate Names:

    SUXINUTIN
    EMESIDE
    CI-366
    PM-671
    CN-10395
    ETHOSUXIMIDE
    NSC-64013
    ZARONTIN
    3-ETHYL-3-METHYLSUCCINIMIDE
    AETHOSUXIMIDE
    GAMMA-METHYL-GAMMA-ETHYL-SUCCINIMIDE
    3-METHYL-3-ETHYLSUCCINIMIDE
    ATYSMAL
    (+-)-2-ETHYL-2-METHYLSUCCINIMIDE
    3-METHYL-3-ETHYLPYRROLIDINE-2,5-DIONE
    THILOPEMAL
    2-METHYL-2-ETHYLSUCCINIMIDE
    ETOSUXIMIDA
    Γ-ETHYL-Γ-METHYL-SUCCINIMIDE
    ALPHA-ETHYL-ALPHA-METHYLSUCCINIMIDE
    ALPHA-METHYL-ALPHA-ETHYLSUCCINIMIDE
    GAMMA-ETHYL-GAMMA-METHYL-SUCCINIMIDE
    ZARONTIN®
    2-ETHYL-2-METHYLSUCCINIMIDE
    ETHOSUXIMIDUM
    3-ETHYL-3-METHYL-2,5-PYRROLIDINEDIONE
    ETHOSUXIMID
    (±)-2-ETHYL-2-METHYLSUCCINIMIDE
    drugbank:00593
    pubchem.compound:3291
    chembl:CHEMBL696
    chemidplus:77-67-8
    rxcui:4135

    Drug Info:

    FDA Approval 1960
    Drug Class small molecule
    Drug Indications Anticonvulsants
    Drug Class anticonvulsants
    Year of Approval 1960
    (2 More Sources)

    Publications:

    Gomora et al., 2001, Block of cloned human T-type calcium channels by succinimide antiepileptic drugs., Mol. Pharmacol.
    Matthews et al., 2001, Effects of ethosuximide, a T-type Ca(2+) channel blocker, on dorsal horn neuronal responses in rats., Eur. J. Pharmacol.
    Wang et al., 2008, Maladaptive homeostatic plasticity in a rodent model of central pain syndrome: thalamic hyperexcitability after spinothalamic tract lesions., J. Neurosci.
    Chen et al., 2002, TTD: Therapeutic Target Database., Nucleic Acids Res.
    Rendic S et al., 1997, Human cytochrome P450 enzymes: a status report summarizing their reactions, substrates, inducers, and inhibitors., Drug Metab Rev
    Bertok S et al., 2017, The association of SCN1A p.Thr1067Ala polymorphism with epilepsy risk and the response to antiepileptic drugs in Slovenian children and adolescents with epilepsy., Seizure
    Ma CL et al., 2014, Association of SCN1A, SCN2A and ABCC2 gene polymorphisms with the response to antiepileptic drugs in Chinese Han patients with epilepsy., Pharmacogenomics
    Haerian BS et al., 2013, SCN1A, SCN2A and SCN3A gene polymorphisms and responsiveness to antiepileptic drugs: a multicenter cohort study and meta-analysis., Pharmacogenomics
    Kumari R et al., 2011, Pharmacogenomic association study on the role of drug metabolizing, drug transporters and drug target gene polymorphisms in drug-resistant epilepsy in a north Indian population., Indian J Hum Genet
  • ETHOSUXIMIDE   CACNA1G

    Interaction Score: 5.82

    Interaction Types & Directionality:
    blocker (inhibitory)
    inhibitor (inhibitory)

    Interaction Info:
    Direct Interaction yes
    Mechanism of Interaction Voltage-gated T-type calcium channel blocker
    Trial Name -

    PMIDs:
    11641441 11274992 19005061 11752352


    Sources:
    TdgClinicalTrial ChemblInteractions TEND TTD

  • ETHOSUXIMIDE   SCN1A

    Interaction Score: 1.03

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    28753467 25155934 23859570 21747585


    Sources:
    PharmGKB

  • ETHOSUXIMIDE   CACNA1I

    Interaction Score: 0.77

    Interaction Types & Directionality:
    blocker (inhibitory)

    Interaction Info:
    Mechanism of Interaction Voltage-gated T-type calcium channel blocker
    Direct Interaction yes

    PMIDs:
    None found


    Sources:
    ChemblInteractions

  • ETHOSUXIMIDE   CACNA1H

    Interaction Score: 0.46

    Interaction Types & Directionality:
    blocker (inhibitory)

    Interaction Info:
    Mechanism of Interaction Voltage-gated T-type calcium channel blocker
    Direct Interaction yes

    PMIDs:
    None found


    Sources:
    ChemblInteractions

  • ETHOSUXIMIDE   CYP3A4

    Interaction Score: 0.03

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    9187528


    Sources:
    PharmGKB

  • TEND: ETHOSUXIMIDE

    • Version: 01-August-2011

    Alternate Names:
    ETHOSUXIMIDE Primary Drug Name

    Drug Info:
    Year of Approval 1960
    Drug Class anticonvulsants

    Publications:

  • TdgClinicalTrial: ETHOSUXIMIDE

    • Version: January-2014

    Alternate Names:

    Drug Info:
    Drug Indications Anticonvulsants
    Drug Class small molecule
    FDA Approval 1960

    Publications:

  • PharmGKB: ethosuximide

    • Version: 18-August-2020

    Alternate Names:

    Drug Info:

    Publications:
    Haerian BS et al., 2013, SCN1A, SCN2A and SCN3A gene polymorphisms and responsiveness to antiepileptic drugs: a multicenter cohort study and meta-analysis., Pharmacogenomics
    Kumari R et al., 2011, Pharmacogenomic association study on the role of drug metabolizing, drug transporters and drug target gene polymorphisms in drug-resistant epilepsy in a north Indian population., Indian J Hum Genet
    Bertok S et al., 2017, The association of SCN1A p.Thr1067Ala polymorphism with epilepsy risk and the response to antiepileptic drugs in Slovenian children and adolescents with epilepsy., Seizure

  • TTD: Ethosuximide

    • Version: 2020.06.01

    Alternate Names:
    D0Q4XQ TTD Drug ID

    Drug Info:

    Publications:

  • ChemblDrugs: chembl:CHEMBL696

    • Version: ChEMBL_27

    Alternate Names:

    Drug Info:

    Publications:

  • ChemblInteractions: CHEMBL696

    • Version: chembl_23

    Alternate Names:

    Drug Info:

    Publications:

Disclaimer: This resource is intended for purely research purposes. It should not be used for emergencies or medical or professional advice.

A finding of a drug-gene interaction or potentially druggable category does not necessarily indicate effectiveness (or lack thereof) of any drug or treatment regimen. A finding of no interaction or no potentially druggable category does not necessarily indicate lack of effectiveness of any drug or treatment regimen. Drug-gene interactions or potentially druggable categories are not presented in ranked order of potential or predicted efficacy.

The dgidb.org website does not provide any medical or healthcare products, services or advice, and is not for medical emergencies or urgent situations. IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY, CALL YOUR DOCTOR OR 911 IMMEDIATELY. Information contained on this website is not a substitute for a doctor's medical judgment or advice. We recommend that you discuss your specific, individual health concerns with your doctor or health care professional.

DGIdb (v4.2.0 - sha1 afd9f30b) • Last updated 2020-10-21